Literature DB >> 6692436

Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect.

H E Skipper, F M Schabel.   

Abstract

Herein we have considered the types of tumor stem cell heterogeneity that might account for (a) fluctuating degrees of response to chemotherapy in similarly treated individuals bearing a particular neoplasm, and (b) classifications of cancers by chemotherapeutic effect. Fluctuating ratios of T/R to T/O stem cells, as predicted by the mutation theory, will account for (a). In different circumstances at least three phenomena might account for (b): growth fraction differences, differences in T/R to T/O stem cell ratios, or differences with respect to pharmacologic sanctuaries. T/R stem cells are primarily responsible for the failure of the best available chemotherapy to cure responsive, refractory, and very refractory experimental neoplasms. The data examined suggest that differences in the T/R to T/O stem cell ratios in different types of cancer may account for their being classed as responsive, refractory, or very refractory. If this be true, what might underlie such differences? The most obvious possibilities are: higher mutation rates to a drug-resistant state in refractory cancers, or some sort of "natural selection" of diverse T/R stem cells in refractory cancers.

Entities:  

Mesh:

Year:  1984        PMID: 6692436

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  11 in total

1.  New strategies in cancer chemotherapy.

Authors:  G Bonadonna
Journal:  Cell Biophys       Date:  1986-12

2.  Sub-micromolar concentrations of retinoic acid induce morphological and functional neuronal phenotypes in SK-N-SH neuroblastoma cells.

Authors:  Emily Harasym; Nicole McAndrew; George Gomez
Journal:  In Vitro Cell Dev Biol Anim       Date:  2017-08-24       Impact factor: 2.416

3.  On mathematical modeling of critical variables in cancer treatment (goals: better understanding of the past and better planning in the future).

Authors:  H E Skipper
Journal:  Bull Math Biol       Date:  1986       Impact factor: 1.758

4.  Absence of structural alterations of the multidrug resistance genes in transitional cell carcinoma.

Authors:  E A Klein; G Allen; W R Fair; V Reuter; R S Chaganti
Journal:  Urol Res       Date:  1990

5.  Postconfluency MDCK monolayers as an in vitro model of solid tumor chemosensitivity.

Authors:  P Skehan; J Thomas; S J Friedman
Journal:  Cell Biol Toxicol       Date:  1986-09       Impact factor: 6.691

Review 6.  Predictive testing in cancer chemotherapy. I. In vivo.

Authors:  P H Slee; A T Van Oosterom; E A De Bruijn
Journal:  Pharm Weekbl Sci       Date:  1985-06-21

7.  Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.

Authors:  G Bonadonna; P Valagussa; A Rossi; G Tancini; C Brambilla; M Zambetti; U Veronesi
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 8.  Some aspects of size-dependent differential drug response in primary and metastatic tumors.

Authors:  I Abe; M Suzuki; K Hori; S Saito; H Sato
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

9.  9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.

Authors:  L Danhauser; W Plunkett; M Keating; F Cabanillas
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Mathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics.

Authors:  Georgy P Karev; Artem S Novozhilov; Eugene V Koonin
Journal:  Biol Direct       Date:  2006-10-03       Impact factor: 4.540

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.